<DOC>
	<DOCNO>NCT00180882</DOCNO>
	<brief_summary>To explore multicenter international prospective randomize study ( phase III ) whether rituximab combine standard French LMB chemotherapy scheme result higher rate EFS LMB chemotherapy scheme alone patient older 18 year Burkitt lymphoma ALL 3 .</brief_summary>
	<brief_title>LMBA02 Protocol Patients With Burkitt Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Burkitt Lymphoma</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Age : 18 year old Histologically cytologically proven Burkitt lymphoma accord WHO classification WHO performance &lt; 3 Informed consent Known HIV positive infection Positive serology HCV HBV ( except vaccination ) Patients previously treat lymphoma cardiac disease contradict anthracycline chemotherapy Psychological psychiatric condition contradict steroid therapy Patients serious renal failure unrelated lymphoma ( serum creatinin level high 150 mmole/L ) Cirrhosis severe hepatic failure unrelated lymphoma Previous malignant disease except basal cell skin carcinoma situ uterine cervix carcinoma Any psychological , familial , sociological geographical condition potentially hamper compliance study protocol followup schedule Primary organ transplant immunosuppressive condition Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2006</verification_date>
</DOC>